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demographic size of ACs) were calculated for selected tariffs. RESULTS: We observed 
lack of consistency in structure and contents of tariff lists and in tariff levels, as 
exempliﬁ ed by: different categorization of services; incomplete listing of services; dif-
ferent terminologies; different levels of detail for common services (e.g. MRI: 2–127 
options by body area and/or complexity); wide ranges of tariffs for most items (e.g. 
specialist visit: c56–c191, general ward per diem: c82–c569, simple MRI: c120–c634). 
Wide variations were also observed for other diagnostic investigations, (non-)surgical 
procedures, laboratory tests and DRGs. CONCLUSIONS: Wide ranges in tariffs for 
health resources commonly used in economic evaluations were identiﬁ ed across ACs, 
with a difference between minimum and maximum values of at least factor 2. There 
exists no evidence on how tariffs are calculated and if they reﬂ ect real cost. Available 
AC tariffs should be used with caution and a simple or weighted average across AC 
tariff lists may be used as proxies for nation-wide costs. Elaboration of a nation-wide 
list would avoid possible bias from analysts in the selection of cost values to obtain 
given results.
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OBJECTIVES: We examined the association between economic evaluation studies 
performed in Spain in 1983–2008 and the burden of disease in the population. 
METHODS: Cross-sectional observational study. Electronic databases (Pubmed/
MEDLINE, SCOPUS, ISI Web of Knowledge, CRD, IME, IBECS) and reports from 
public agencies were systematically reviewed. Inclusion and exclusion criteria and a 
set of variables were deﬁ ned to analyze the characteristics of the papers selected. Using 
the Global Burden of Disease (GBD) study classiﬁ cation the following measures were 
calculated: years of life lost (YLLs), years lived with disability (YLDs), disability-
adjusted life-years (DALYs), and mortality by cause. Correlation and linear regression 
models were used. RESULTS: Cardiovascular diseases (15.7%), infectious and para-
sitic diseases (15.3%), and malignant neoplasms (13.2%) were the conditions most 
commonly addressed. Accidents and injuries, congenital anomalies, oral conditions, 
nutritional deﬁ ciencies and other neoplasms were the categories with a lowest number 
of studies (0.6% from the total for each of them). The disease sub-categories most 
prevalent in the studies were lower respiratory infections (5.7%), ischemic heart 
disease (5.7%), hepatitis B and C (3.3%) and HIV/AIDS (3.1%). For GBD categories 
(n = 20), a correlation was seen with: mortality 0.67 (p = 0.001), DALYs 0.63 (p = 
0.003), YLLs 0.54 (p = 0.014), and YLDs 0.51 (p = 0.018). By diseases sub-categories 
(n = 51), the correlations were low and non statistically signiﬁ cant. CONCLUSIONS: 
There is a mild-moderate association of economic evaluations with the main causes 
of burden of disease. For some conditions, the data show over or under-representation 
of studies related to their burden generated. The burden of disease is a criterion that, 
in combination with efﬁ ciency and equity, would allow to set recommendations to 
guide debates on health research priority setting.
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BACKGROUND: The major focus of the history of economic thought has been 
devoted to deﬁ ning a scientiﬁ c theory of value. An even harder task entails formulating 
a theory of intertemporal value. Work on this theory date back to the birth of modern 
economic thought. For example, some authors have argued that an intertemporal 
utility based theory of value involves the explanation of a quantity which can be 
directly observed and measured in terms of a quantity which cannot. Major current 
debates on discounting therefore surround the need for a scientiﬁ c deﬁ nition and the 
ethics towards intergenerational justice. OBJECTIVES: We investigate how several 
current issues in discounting might be irrelevant by adopting a Neo-Ricardian view 
of intertemporal value by recursively applying valuation of a commodity from value 
of input commodities, thereby simplifying to the Physiocratic School. We further 
investigate how our empirical model might be extended to current utilitarian philoso-
phy. METHODS: We adopt a Srafﬁ an approach and devise a pure value-growth 
matrix that relies only on empirical data. We ﬁ rst derive a 2 × 2 matrix and then a 3 
× 3 matrix. We use health effects, income and a third externality for the derivations. 
RESULTS: It seems that the Neo-Riccardian approach provides the necessary require-
ments towards satisfying a scientiﬁ c deﬁ nition of intertemporal value and allows 
extension of the classical framework of health and wealth with a 3rd dimension of 
externalities. Furthermore, by redeﬁ ning the pure growth term in our 2 × 2 matrix 
with the Ramsey discount rate, our results simplify to current economic theory. 
CONCLUSIONS: Although modern economic theory explains value from a utilitarian 
viewpoint, it seems that it lacks robustness in explaining intertemporal value. There-
fore, we suggest that the Srafﬁ an School of economic thought should also be consid-
ered when attempting to formulate a discount rate for health effects, within a concept 
of sustainable growth.
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OBJECTIVE: To verify the reliability of the methodology used in the manufacturers’ 
Budget Impact Analyses (BIAs) submitted in reimbursement dossier to Polish HTA 
Agency, we compared public payer (National Health Fund—NHF) actual expendi-
tures on selected drugs with their estimated costs. METHODS: BIAs of medicines 
reimbursed for at least one year and assessed previously in Agency were selected for 
the analysis. The BI estimated by the manufacturer in the ﬁ rst year after product’s 
introduction to reimbursement was used. Estimated size of target population was 
compared with the actual one. The actual data was obtained from the NHF. BIAs for 
selected medicines were critically appraised to determine any variables that may have 
affected its reliability. RESULTS: 20 BIAs met inclusion criteria and were included 
into the study. Forty-ﬁ ve percent (9/20) of the BI expenditures were underestimated. 
Median and mean difference between actual and estimated expenditure were 17,22% 
and 30,25% respectively. The overestimation was found in 55% BIAs (11/20); median 
= 262,26%, mean difference = 2267,25%. Population size was underestimated in 65% 
(13/20) of the BIAs. Median and mean difference between actual and estimated popu-
lation were 25,61% and 33,93% respectively. Overestimation of the population was 
found in 35% (7/20) of the BIAs; median = 566,67%, mean difference = 573,28%. 
The main factors that could inﬂ uence differences between predictions and actual 
spending were: underestimated (65%) or overestimated (35%) number of patients 
eligible for treatment, overestimated (30%) or underestimated (25%) market share, 
wrong assumption on 100% compliance (15%). CONCLUSION: The study has dem-
onstrated large variances between predicted budget impact and actual expenditures on 
drugs. It also revealed signiﬁ cant weaknesses in the quality of submitted BIAs, e.g.: errors 
in calculations, very limited data provided by manufacturer that unable to complete revi-
sion and reproduce of ﬁ gures in the calculation.
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As they are currently used thresholds for cost per QALY may provide a disincentive 
for companies to invest in research for therapies that prolong life in conditions with 
an already high treatment cost. Cost per QALY thresholds, although not the sole basis 
for decision making are a major inﬂ uence on whether a technology is considered 
cost-effective by NICE. Discussions have centred on the most appropriate threshold 
level and how its value should be determined. However a consequence of cost per 
QALY thresholds that is not discussed is the impact they may have on future health 
care research. The cost per QALY for renal dialysis has been estimated at £30,0001, 
the higher end of what NICE considers acceptable. We have therefore reached the 
ceiling for the cost of treating renal disease. Assuming that utility is not improved a 
treatment that extends life will be at additional cost and have a cost per QALY greater 
than £30,000. Manufacturers of health care technologies may consider that the risk 
of not getting a product approved on cost-effectiveness grounds is not worth the 
ﬁ nancial investment in its development. As health care costs continue to grow the 
management costs of more conditions will exceed £20,000 per year and future 
research may be stiﬂ ed as manufacturers seek to develop products that replace rather 
than add to current treatments. Since the background treatment cost would cancel out 
in an incremental analysis a treatment could be more cost-effective than the one it 
replaces but perversely can still be at an increased cost which raises the cost per QALY 
of standard treatment above £20,000 or £30,000. As treatment costs for more condi-
tions increase to threshold values (even if they are raised) manufactures may be advised 
to consider realigning their portfolio and investment to other diseases.
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OBJECTIVES: The objective of the CRRéa study is to assess the real daily cost of a 
patient’s stay in ICU in France. We present here preliminary results regarding the 
average time spent per patient by different health caregivers. METHODS: A prospec-
tive multicentric health economic study was performed in 23 ICUs of different French 
hospitals randomly selected from the PMSI database (French National Hospital data-
base). In a one day study, 5 adult patients were randomly selected among patients 
with a simpliﬁ ed severity score ≥ 15 in each ICU. Data on all the resources used, 
treatments administered, biological tests performed, etc. and time spent by different 
health caregiver to take care of each patient over a 24 hour period (direct and indirect 
interventions) were collected through a time and motion analysis method involving 
the professionals themselves. RESULTS: A total of 109 patients (median age = 66 
years, 65% males) of 22 intensive care units (15 polyvalent, 3 surgical and 4 medical 
ICUs) were included. 104 of them were followed over 24 hours (there were 2 deaths 
and 3 early withdrawals). On the day of the study, 84% of patients were mechanically 
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ventilated with a median SOFA score = 6. The median cumulated time dedicated to 
one patient by physicians, nurses and caregivers was 10h20 over the 24-hour period 
(1h15 by physician, 6h08 by nurses and 2h57 by caregivers). CONCLUSIONS: The 
median time of more than 10 hours directly dedicated to a patient is a key information 
for the estimation of the real cost of one day stay in ICU
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OBJECTIVES: This study aims to identify how medication compliance and/or persis-
tence were assessed in the cost-effectiveness analysis, and what the impact was on 
ICER(Incremental cost-effectiveness ratio). METHODS: Pharmacoeconomic studies 
with compliance and/or persistence measures, had published from March 2005 to 
February 2010, were searched through MEDLINE. Articles were included if they 
integrated medication compliance and/or persistence into the economic analysis 
model. We reviewed the target diseases, the model designs, and the impact of non-
compliance on the treatment costs and effects. After that, the results were compared 
with a previous review article of ISPOR MCP(Medication compliance and persistence 
special interest group) had conducted in 2007. RESULTS: The search identiﬁ ed 77 
articles, and 10 of them were selected. Even though the overall kinds of target diseases 
were different, most of them were chronic diseases, which have remission and relapse 
as common characteristics. Variety of modeling techniques such as decision-analysis 
and Markov model, DES (Discrete event simulation) were used for the evaluations. 
In decision-analysis models, the branches of decision trees represented different level 
of compliance. In case of Markov models, transition probabilities assumed to be higher 
for those patients who were non-persistent or non-adherent to treatment. Finally, 
considering the effect of compliance and/or persistence, it may cause decrease of ICER 
for new intervention. CONCLUSIONS: We found that incorporating compliance and/
or persistence into economic evaluations lead to favorable results to new intervention. 
However, there was a lack of methodological rigor and consistency in deﬁ nition. 
Therefore, development of guidance is needed for measurement, analysis, interpreta-
tion, and application of compliance and persistence from variety of data sources.
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BACKGROUND: Discounting health effects remains a matter of great debate these 
days. Currently, discussion focuses on whether health effects should be discounted at 
the same rate as costs or not. High discount rates for health effects are impacting 
negatively on the cost-effectiveness of screening and vaccination programs. Discount-
ing health at a lower rate than wealth has however been argued to result in theoretical 
inconsistencies and practical unnecessary delays in implementation of health pro-
grams. Many authors have therefore assumed that there is a one-to-one relationship 
between health and wealth. OBJECTIVES: We investigate the rationality of several 
assumptions involved towards current discounting procedures. We especially investi-
gated the assumption of a one-to-one relationship between health and wealth. 
METHODS: We performed a literature review to link the issues in current methods 
of discounting health effects with the assumptions involved. Furthermore, we analyzed 
other possible linkages of health rather than with wealth only. RESULTS: We noticed 
that although income might depict the marginal substitution between all commodities, 
it seems that externalities are not accounted for. Yet, research has shown that all forms 
of economic growth exert intrinsically negative population health effects among the 
communities that are most directly involved in the transformations which it entails. 
This may obviously impact on valuation of health states and preferences, measured 
using instruments as the EuroQol-5D. These arguments support differential discount-
ing of health effects, and potential further extensions such as differential discounting 
of life and quality. CONCLUSIONS: Although there might be a relationship between 
wealth and health, it appears that externalities may play an additional role on the 
quality of life. Therefore, it seems that we should regard the discounting problem of 
health effects as an interlinked system, rather than an equation with only health and 
wealth and allow differential discounting of, and potentially even within, health 
effects.
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Three of the more common methods of estimating the optimal price for prospective 
pharmaceutical products are willingness-to-pay, value-based price appraisal, and refer-
ence price benchmarking assessments. Each method in itself, however, has inherent 
limitations. The objective of this study is to present a novel technique in pharamceuti-
cal price estimation for arriving at an evidence based price-point. Willingness-to-pay, 
as assessed through primary research, is limited by lack of knowledge of product prices 
and the disconnect between respondent answers and real-life price acceptance. Value-
based price appraisals, utilizing cost-of-treatment models to estimate the price at which 
new products are cost-effective relative to other options, are subject to error and 
interpretation and are rarely taken at face value by stakeholders who drive price 
acceptance. Reference price benchmarking, looking to market analogues to gauge 
appropriate price-points for new products, can be a good starting point but does not 
take into account unique product differences, perceived or real, of new products. To 
address gaps and weaknesses of any given individual method, our method of determin-
ing optimal product price uses all three pricing methodologies to triangulate on a 
recommended price-point. Market analogues are used as a base-price starting point. 
a value-based cost-of-treatment model is used to determine potential cost-savings that 
can be offset in price. Finally, primary research is used to determine how to modify 
that price based on perceived differences in the target product, and the how cost-
savings might be considered in price. 
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Databases & 
Management Methods
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OBJECTIVES: Primary care patient data are increasingly used for research and record-
ing of death is important as it helps deﬁ ne end of follow-up and mortality may be a 
study outcome. This study compared recording of death in a UK primary care database 
with national death rates for England, Wales, Scotland and Northern Ireland (NI). 
METHODS: The annual number of deaths (1990 to 2008) for each country was 
collected after the mortality recording quality threshold from The Health Improvement 
Network (THIN) database. THIN holds longitudinal anonymised primary care 
medical records from an increasing number of practices over time and currently 
contains data from more than 450 practices throughout the UK. Annual age and 
gender speciﬁ c person time was estimated and multiplied with annual age, gender and 
country speciﬁ c death rates to derive the expected number of deaths. Observed deaths 
divided by expected deaths provided the standardised mortality ratio (SMR) and 
Byar’s approximation formula was applied to derive 95% conﬁ dence intervals (CI). 
An SMR close to 1.0 indicates that recorded deaths are near national rates. RESULTS: 
The average annual number of practices was 263.5 (standard deviation (SD):80.2) for 
England, 18.8 (SD:8.5) for Wales, 33.6 (SD:17.0) for Scotland, and 14.0 (SD:7.6) for 
NI. Average annual death rate per 1,000 population in THIN was 10.41 (SD:1.05) 
overall, 10.38 (SD:1.02) in England, 11.25 (SD:1.45) in Wales, 11.03 (SD:1.54) in 
Scotland and 8.29 (SD:0.77) in NI. The average annual SMR was 0.88 (SD:0.02) 
overall, 0.88 (SD:0.02) in England, 0.94 (SD:0.05) in Wales, 0.94 (SD:0.10) in Scot-
land and 0.91(SD:0.07) in NI. CONCLUSIONS: The observed death rates were 
slightly lower than expected (SMR < 1) over time and in each country, especially in 
England. Social deprivation impacts death rates and as unadjusted for this could 
explain some variation. Reasons for lower rates need to be investigated further.
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OBJECTIVES: The objective of the study is to obtain behaviour of the cost’s relative 
average weights of the assistance with the retrospective application of the Adjusted 
Clinical Groups (ACG’s) in 16 teams of Primary Care with an attended population in 
the clinical practice use. METHODS: Multicentre, retrospective study based on elec-
tronic records of patients seeking care during 2008 in the regions of Aragon, Balears 
and Catalonia. Main measurements: universal variables (age, sex, health service-family 
practice/paediatrics) and dependent variables: episodes and total cost (visits, diagnostic 
test, referrals, drugs). The ACG case-mix System software (version 8.2; N = 106) 
classiﬁ ed subjects into a single category for a given annual resource consumption. The 
model of cost per each patient was established differencing the ﬁ x cost and the vari-
able. Outlier patients were considered those surpassing T = Q3 + 1.5(Q3-Q1) = 
c1778.6 for total cost expenditure. Log transformation of the dependent variable was 
carried out to reduce skewness of the distribution and make it close to normal. 
Explanatory power was calculated by coefﬁ cients of determination (R2). Statistical 
software: SPSS, P < 0.05. RESULTS: The total number of the studied patients was 
227,235 (intensity of use: 75.6%), with an average 4.5 ± 3.2 episodes. The age average 
was of 44.1 ± 23.7 years, 56.6% women (13.5% paediatrics). The distribution of 
costs was c148,657,137. The total unitary cost per patient/year c654.2 ± 851.7 (rela-
tive weights of reference). Patient’s case-mix: 57.2% of the study population was 
grouped into 10 ACG. The explanatory power of the ACG classiﬁ cation system was 
36.3% (Ln: 41.2%), P < 0,001. a total of 6.2% of patients were considered Outliers 
(N = 14.066). CONCLUSIONS: The ACG are an acceptable system of classiﬁ cation 
of patients in situation of clinical practice use. Some ACG classiﬁ cation categories 
should be separeted due to the high outliers number.
